4QK Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
High Gross Margins / Unit EconomicsVery high gross margins indicate strong unit economics and technical differentiation in enzyme products. Sustained margins (TTM ~82%, Q1 product 71%) provide durable pricing power and the ability to fund R&D and scale-up investments even while operating losses narrow.
Accelerating Revenue And Commercial TractionMaterial top-line acceleration and positive TTM growth reflect increasing adoption of Codexis offerings. Repeated partner engagements and a growing sales pipeline suggest the business is moving from R&D toward more consistent commercial revenue, supporting sustainable revenue expansion over months.
Profitable Small-Molecule Biocatalysis BaseA profitable, recurring small-molecule enzyme business provides a stable cash-generating backbone and customer validation. Supplying 13 branded products reduces single-product concentration risk and underwrites platform investment, making long-term commercialization less binary.
Bears Say
Negative Free Cash Flow And Cash BurnSustained negative operating and free cash flow requires ongoing external funding or drawdown of reserves. Even with management saying cash funds operations through 2027, persistent FCF deficits limit strategic optionality and raise dilution or refinancing risk if revenue milestones slip.
Rising Leverage And Weakened Balance SheetMaterial increase in leverage materially reduces financial flexibility and increases servicing risk. A high debt-to-equity ratio combined with declining equity and persistent losses raises the cost of capital and constrains the company's ability to absorb execution delays or pursue opportunistic investments.
Scale-up And Partnership Execution RiskThe business case depends on successful technical scale-up and partner conversions; moving to 0.5 kg and GMP readiness involves significant engineering and timing risk. Delays or failures would compress margins, defer milestone/royalty revenue, and strain the projected back-half-weighted revenue profile.
Codexis News
4QK FAQ
What was Codexis’s price range in the past 12 months?
Currently, no data Available
What is Codexis’s market cap?
Codexis’s market cap is CHF190.80M.
When is Codexis’s upcoming earnings report date?
Codexis’s upcoming earnings report date is Jul 30, 2026 which is in 21 days.
How were Codexis’s earnings last quarter?
Codexis released its earnings results on May 07, 2026. The company reported -CHF0.081 earnings per share for the quarter, beating the consensus estimate of -CHF0.111 by CHF0.03.
Is Codexis overvalued?
According to Wall Street analysts Codexis’s price is currently Undervalued.
Does Codexis pay dividends?
Codexis does not currently pay dividends.
What is Codexis’s EPS estimate?
Codexis’s EPS estimate is -0.11.
How many shares outstanding does Codexis have?
Currently, no data Available
What happened to Codexis’s price movement after its last earnings report?
Codexis reported an EPS of -CHF0.081 in its last earnings report, beating expectations of -CHF0.111. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Codexis?
Currently, no hedge funds are holding shares in CH:4QK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Codexis Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
CHF5.93 (― Downside)
CHF5.93 (― Downside)
Insider Transactions
Sold Shares
Worth CHF5.0K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-65.50%
12-Months-Change
Fundamentals
Return on Equity
-68.09%
Trailing 12-Months
Asset Growth
0.37%
Trailing 12-Months
Company Description
Codexis
Codexis, Inc. is a biotechnology firm dedicated to the discovery, development, and commercialization of enzymes and other protein-based solutions. Its diverse portfolio encompasses advanced biocatalyst products and related services, specialized chemical intermediates vital for subsequent processing steps, and proprietary biocatalyst panels and kits that empower clients to conduct effective chemistry screening. The company also extends its expertise through biocatalyst screening and sophisticated protein engineering services. Central to its operations is the proprietary CodeEvolver protein engineering technology platform. This innovative platform is instrumental in crafting and delivering high-performance biocatalysts capable of driving chemical transformations, thereby significantly enhancing the efficiency and productivity of manufacturing processes. Beyond industrial applications, the CodeEvolver platform is also leveraged for identifying novel biotherapeutic drug candidates for targeted human diseases, as well as for developing enzymes essential for molecular biology research and in vitro diagnostic applications. Primarily serving pharmaceutical manufacturers, Codexis distributes its products through its dedicated direct sales and business development teams across the United States and Europe. Established in 2002, the company maintains its headquarters in Redwood City, California.
4QK Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlights strong top-line acceleration (Q1 revenue +≈103%), materially improved product margins (71% vs 55%), a substantially reduced net loss, promising platform innovations (stereochemical control) and a healthy sales funnel with CDMO interest. Offsetting these positives are reliance on a large one-time Merck revenue recognition for the quarter, a declining cash balance, remaining technical and scale-up risks (100 g to 0.5 kg target), and pending clinical/efficacy data to validate stereochemistry benefits. Management reiterated full-year guidance and expects the business to be operationally ready with a new GMP facility by end of 2027, but execution and partnership conversion timing will be critical.View all CH:4QK earnings summaries4QK Stock 12 Month Forecast
Average Price Target
CHF5.93
Cartesian Therapeutics
―
Cabaletta Bio
―
Elicio Therapeutics
―
Vor Biopharma
―
OmniAb
―
Options Prices
Currently, No data available
---